BRAIN and NERVE Shinkei Kenkyu no Shinpo Volume 69, Issue 7 (July 2017)

Alzheimer's Therapeutic Research Institute Hiroyuki Shimada 1 , Yuichi Kato 2 , Hisako Fujii 2 , Hiroshi Mori 3 1Clinical Research Center for Dementia, Graduate School of Medicine, Osaka City University 2Department of Drug & Food Clinical Evaluation, Graduate School of Medicine, Osaka City University 3Department of Clinical Neuroscience, Graduate School of Medicine, Osaka City University Keyword: アルツハイマー病 , ATRI , 臨床研究 , ACTC , Alzheimer's disease , ATRI , clinical study , ACTC pp.856-861
Published Date 2017/7/1
  • Abstract
  • Look Inside
  • Reference


The Alzheimer's Therapeutic Research Institute (ATRI) was established in 2015 after ATRI director, Paul Aisen, and his fellow experts in therapeutic interventions for Alzheimer's disease (AD) moved from the Alzheimer's Disease Cooperative Study (ADCS) at the University of California to the Keck School of Medicine of the University of Southern California. The National Institute on Aging (NIA) decided to commit $14 million to the ATRI via an Alzheimer's Clinical Trials Consortium (ACTC). The ATRI supports various studies such as the Anti-Amyloid Treatment in Asymptomatic Alzheimer's study ("A4 study"), Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3), Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN), and The Alzheimer's Disease Neuroimaging Initiative-Depression Project (ADNI-D). The ATRI will share all relevant data and materials with the academic community, corporations, and government organizations. The ATRI is overseen by a Data and Safety Monitoring Board (DSMB), which comprises of leading experts in the field of Alzheimer's research and acts independently. The ATRI is slated to play a central role in clinical dementia research in the US in near future.

Copyright © 2017, Igaku-Shoin Ltd. All rights reserved.


BRAIN and NERVE-神経研究の進歩
69巻7号 (2017年7月)
電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院